Biotech IPOs roared back in 2017, but what will the next year bring?

Nasdaq
The window blew open from Q2 this year, and is not showing any signs of closing anytime soon

Reporting on biotech public offerings in 2016 was a hit-or-miss affair. If we’re honest, it was mainly a miss: Many were cancelled or came out of the gate with low-end offerings as the window appeared to be all but closed.

There was a crack in early 2017 and some light came in, but since the second quarter IPOs have ramped up, with 40 U.S. biotechs getting off their IPOs to date. That's a dozen more than 2016, with deal values also doubling, from $2 billion to $4 billion, according to Renaissance Capital.

And the market saved the best for last: Denali Therapeutics managed to raise a massive $250 million. As the biggest biotech listing of the year, the IPO sets it up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

And it wasn’t an outlier, as Fierce 15 2016 winner and rare disease biotech Rhythm Pharmaceuticals topped its expectations in its IPO, selling more shares—at a higher price—than expected, hitting $120 million.

Not every company has been successful, however. Accelerated Pharma pulled its troubled attempts at an IPO back in August—although such moves have been the exception rather than the rule this year.

But many biotechs still remains cautious. With a series of CEOs of private companies telling me they are still awaiting the right time and environment, 2018 could prove to be that time, if the momentum built up over the past few quarters continues into the new year, and beyond.

Suggested Articles

Biotronik received FDA approvals for six high-voltage cardiac rhythm management devices for treating and resynchronizing tachycardia and arrhythmias.

IRhythm’s ECG patch was able to improve atrial fibrillation diagnoses and lower numbers of ER visits by shifting patients to outpatient settings.

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.